Pharmacogenomic study of heart failure and candesartan response from the CHARM programme

AIMS: The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) programme consisted of three parallel, randomized, double‐blind clinical trials comparing candesartan with placebo in patients with heart failure (HF) categorized according to left ventricular ejection...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubé, Marie‐Pierre, Chazara, Olympe, Lemaçon, Audrey, Asselin, Géraldine, Provost, Sylvie, Barhdadi, Amina, Lemieux Perreault, Louis‐Philippe, Mongrain, Ian, Wang, Quanli, Carss, Keren, Paul, Dirk S., Cunningham, Jonathan W., Rouleau, Jean, Solomon, Scott D., McMurray, John J.V., Yusuf, Salim, Granger, Chris B., Haefliger, Carolina, de Denus, Simon, Tardif, Jean‐Claude
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715825/
https://www.ncbi.nlm.nih.gov/pubmed/35736394
http://dx.doi.org/10.1002/ehf2.14026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715825/
https://www.ncbi.nlm.nih.gov/pubmed/35736394
http://dx.doi.org/10.1002/ehf2.14026

Ejemplares similares